troglitazone has been researched along with Barrett Epithelium in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takashima, T | 1 |
| Fujiwara, Y | 1 |
| Hamaguchi, M | 1 |
| Sasaki, E | 1 |
| Tominaga, K | 1 |
| Watanabe, T | 1 |
| Oshitani, N | 1 |
| Higuchi, K | 1 |
| Arakawa, T | 1 |
1 other study available for troglitazone and Barrett Epithelium
| Article | Year |
|---|---|
Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Apoptosis; Barrett Esophagus; Biopsy; Bisbenzimidazole; Blotting, Western; C | 2005 |